GE HealthCare is rolling out a new computed tomography (CT) system to support practitioners in diagnosing complex coronary artery disease (CAD) cases.
The company’s new Revolution Vibe system was formally launched at the American College of Cardiology (ACC) 2025 meeting, taking place in Chicago from 29 to 31 March.
Go deeper with GlobalData
According to GE HealthCare, Vibe, which allows for cardiac CT angiography (CCTA), in which contrast dyes are used to visualise blood vessels to aid in diagnosing advanced cardiovascular diseases (CVD) such as atrial fibrillation and heavily calcified coronaries, is critical at a time where CVD incidence is seeing a dramatic rise worldwide.
CVDs are the leading cause of mortality worldwide, with research forecasting that total coronary and stroke deaths in the US could rise by around 18% – indicative of around 67,000 additional coronary deaths per year – by 2030. Between 2025 and 2050, CVD prevalence is forecast to increase by a staggering 90%.
Jean-Luc Procaccini, president and CEO of molecular imaging and computed tomography at GE HealthCare, commented: “Expanding access to CCTA is crucial for managing the rising prevalence of CVD, ensuring timely and accurate diagnoses for a larger patient population.
“Our introduction of Revolution Vibe underscores our commitment to this mission.”
Vibe features Unlimited One-Beat Cardiac, a technology GE HealthCare says is intended to deliver “consistent, high-quality” images in patient exams. The system’s TrueFidelity DL images for cardiac and SnapShot Freeze 2 support further image quality while ECG-less cardiac means the system can obtain CT scans without the need for a patient-attached ECG monitor.
To speed up cardiac scans, Vibe’s AI-based Effortless Cardiac Workflow automatically selects protocols and positions patients ahead of a scan to expedite procedure times and simplify protocols for “junior or inexperienced technologists”.
According to Dr Christopher Ahlers, radiologist at Radiomed, a Germany-based radiology practice and early adopter of Vibe, GE HealthCare’s system has doubled its CCTA capacity while reducing scan times and improving image quality.
Ahlers said: “By adopting Revolution Vibe, we have improved operational efficiency, increased diagnostic confidence, and elevated patient satisfaction, positioning us at the forefront of cardiac care.”
GE HealthCare recently released a new ultrasound system that presents a “significant advancement” in breast cancer screening, according to market analysis.
At this year’s ACC meeting, GE HealthCare revealed plans to launch Flyrcado, a unit-dose PET myocardial perfusion imaging (MPI) agent intended for patients with known or suspected CAD. The US Food and Drug Administration approved the injection last year.
